GT Biopharma Inc (GTBP)

$0.66 -0.03 (-3.71%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	7.76M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	678,700
Avg Vol	1,541,484
Day's Range	N/A - N/A
Shares Out	10.64M
Stochastic %K	30%
Beta	1.17
Analysts	Sell
Price Target	$8.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

NOCKNOCK Jan. 14 at 6:33 PM

$GTBP

0 · Reply

gata2016 Jan. 12 at 6:12 PM

$GTBP Good bounce back today. Shouldnt be too much longer until we get some news.

0 · Reply

rogersmyth Jan. 9 at 5:39 PM

$GTBP BREAKOUT coming early next week.

0 · Reply

rogersmyth Jan. 9 at 5:39 PM

$GTBP Bought 23,000 shares.

0 · Reply

Shyam27 Jan. 9 at 4:36 PM

$GTBP when is news out or significant event

1 · Reply

pumperblower Jan. 9 at 10:24 AM

$GTBP data should be out next week but the biggest issue here is that they will run out of cash in a few weeks and at the current share price it means huge dilution. Cohort 4 data might be positive but its a small step that won't get the share price higher as every one knows that dilution will come 5 minutes after the cohort 4 data..

1 · Reply

NOCKNOCK Jan. 9 at 1:26 AM

$GTBP

0 · Reply

gata2016 Jan. 8 at 5:15 PM

$GTBP As of January 7, 2026, the stock closed at $0.732. Analysts' average one-year price targets suggest a significant potential increase, with forecasts ranging from $8.08 to $8.40. I dont think it will be that high, but worth the shot.

0 · Reply